Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Assets (2017 - 2025)

Autolus Therapeutics' Non-Current Assets history spans 9 years, with the latest figure at $153.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 25.75% year-over-year to $153.2 million; the TTM value through Dec 2025 reached $577.8 million, up 36.49%, while the annual FY2025 figure was $153.2 million, 25.75% up from the prior year.
  • Non-Current Assets reached $153.2 million in Q4 2025 per AUTL's latest filing, up from $147.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $153.2 million in Q4 2025 to a low of $51.5 million in Q3 2022.
  • Average Non-Current Assets over 5 years is $96.8 million, with a median of $97.1 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: plummeted 39.74% in 2021, then skyrocketed 89.67% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $58.6 million in 2021, then rose by 10.06% to $64.5 million in 2022, then surged by 55.15% to $100.1 million in 2023, then rose by 21.7% to $121.8 million in 2024, then increased by 25.75% to $153.2 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Non-Current Assets are $153.2 million (Q4 2025), $147.4 million (Q3 2025), and $146.7 million (Q2 2025).